Christian Koloko flies in for the alley-oop slam
Summerside's plan to revitalize its downtown is giving local businesses hope. Many shops have closed down or moved away, but the city is trying to breathe new life into the area. CBC's Connor Lamont reports.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access
VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ('Rakovina' or the 'Company') (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC). DTC eligibility streamlines the process for U.S. investors to trade Rakovina shares, enhancing liquidity and broadening market accessibility. DTC is a subsidiary of the Depository Trust & Clearing Corporation (DTCC), the largest securities depository in the world, providing settlement services to major U.S. stock exchanges. 'Achieving DTC eligibility is a meaningful step forward in increasing Rakovina's visibility and accessibility to a broader base of institutional and retail investors,' said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. 'It removes a key barrier to efficient trading in the U.S., enhances liquidity, and establishes the foundation for deeper engagement with U.S. capital markets as we continue to execute our growth strategy.' Supporting Strategic Growth and Shareholder Value The designation eliminates previous barriers to entry for U.S. investors by enabling Rakovina shares to be traded electronically, reducing costs and processing times. This development supports the company's broader strategy to increase market participation and deliver long-term value to shareholders. The DTC announcement comes as Rakovina continues to advance its preclinical programs and explore strategic partnerships in AI-enhanced diagnostics and oncology therapeutics. Additional corporate developments are expected in the coming months as the company builds on its momentum and executes on its strategic roadmap. About Rakovina Therapeutics Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact: Michelle Seltenrich, BSc MBA Director, Corporate Development IR@ 778-773-5432Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
June inflation expected to show tariff-driven uptick as Trump escalates trade threats
June's Consumer Price Index (CPI) is expected to show prices rose at a faster clip compared to May. The report, due Tuesday at 8:30 a.m. ET, comes as investors closely monitor whether President Trump's tariffs are starting to filter through to what consumers pay, even as inflation data has so far remained more resilient than expected. According to Bloomberg data, headline CPI is expected to have increased 2.6% year over year in June, up from a 2.4% rise in May. On a monthly basis, prices are forecast to climb 0.3%, marking an acceleration from the 0.1% gain the prior month. On a "core" basis, which strips out volatile food and energy prices, the annual inflation rate for June is expected to come in at 2.9%, a slight pickup from May's 2.8%. Core prices are also projected to climb 0.3% month over month, outpacing the previous 0.1% rise seen in May. In May, falling car and apparel prices, categories seen as early indicators of tariff impacts, contributed to a cooler-than-expected core CPI reading. But economists expect those trends to reverse in June, potentially pushing core inflation higher. Read more: How to protect your savings against inflation The report lands amid renewed trade tensions between the US and other countries. President Trump has unveiled new letters to over 20 countries outlining tariffs ranging from 20% to 50%, including a 35% duty on Canadian goods and 30% tariffs on imports from Mexico and the European Union. He has also floated sweeping 15% to 20% tariffs on most trading partners. The EU, in response, is scrambling to negotiate while preparing potential countermeasures. The back-and-forth raises fresh questions about the Federal Reserve's rate-cutting path. Markets still expect the central bank to hold rates steady at its policy meeting in two weeks, largely due to uncertainties on how tariffs will trickle through to prices. "The June CPI report is likely to show inflation beginning to strengthen again, albeit not enough to alarm Fed officials at this juncture," Wells Fargo economist Sarah House wrote in a note. "The next three months will mark a key stretch of inflation data," she added, noting that while inventory front-running has so far limited price hikes, "it will become increasingly difficult for businesses to absorb higher import duties as pre-tariff stockpiles dwindle." Wells Fargo expects core goods prices to continue rising in the second half of the year as those buffers wear off, although House noted the pass-through to consumers may be limited: "Amid a softer labor market and services inflation dissipating a bit more, the pickup in core inflation stemming from tariffs is likely to look more like a bump than a spike." Bank of America economists Stephen Juneau and Jeseo Park also expect core CPI inflation to accelerate, driven by a rebound in used car prices and broad-based hikes likely linked to tariffs. On the services side, they see inflation firming due to rising medical costs, travel-related prices, and stronger shelter price increases. And Goldman Sachs echoed similar concerns, writing, "Going forward, tariffs will likely provide a somewhat larger boost to monthly inflation," while projecting core CPI gains of 0.3% to 0.4% in the coming months. The firm expects a sharp pickup in core goods inflation but sees only limited effects on services. Still, Goldman anticipates inflation pressures to ease later this year as housing and labor market dynamics cool. Allie Canal is a Senior Reporter at Yahoo Finance. Follow her on X @allie_canal, LinkedIn, and email her at Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Carney set to meet with cabinet to weigh response to Trump's 35% tariff threat
OTTAWA — Prime Minister Mark Carney will meet with his cabinet today for the first time since U.S. President Donald Trump threatened to impose steep new tariffs on Canada. Trump said in a letter to Carney last week that the United States will put a 35 per cent tariff on Canadian goods starting Aug. 1. The White House says that new tariff wouldn't apply to goods that are compliant with the Canada-U.S.-Mexico Agreement on trade. Canada has yet to respond formally to the latest threat, or to Trump's recent moves to impose lofty tariffs on copper imports and double existing levies on steel and aluminum. Carney and Trump agreed last month to work toward a new trade and security pact by July 21, but the U.S. president unilaterally pushed back the timeline to secure a deal. Carney is also set to meet with Canada's premiers next week. This report by The Canadian Press was first published July 15, 2025. The Canadian Press Sign in to access your portfolio
